上海医疗龙头，60天狂飙140亿

Core Insights - Huajian Medical has made significant strides in the digital asset sector, with the completion of the ETHK building in Nanjing, which is dedicated to the research and development of Real World Asset (RWA) digitalization technology [2][11] - The company's market capitalization surged from approximately HKD 30 billion in mid-July to HKD 170 billion by September 19, reflecting a substantial increase of about HKD 140 billion [4] - The founder's share value increased by approximately HKD 40 billion during this period, indicating strong investor interest and confidence in the company's new direction [7] Company Developments - The ETHK building, with a total area of about 70,000 square meters, aims to gather over 5,000 technical experts and partners, establishing one of the strongest RWA technology teams globally [13] - Huajian Medical has rebranded itself as "Huajian Digital Industry Group" and "ETHK Labs Inc." to reflect its new focus on digital assets and Web3 trading platforms [17][18] - The company has formed joint ventures, including ETHK INC and ETHK HOLDINGS LIMITED, to develop a decentralized financial platform and integrate industry resources [20] Strategic Moves - In July, Huajian partnered with BGI's Huada Gongying to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [9] - The company acquired a 20.31% stake in Guofu Quantum for HKD 31 billion, positioning itself as a major player in the traditional and blockchain finance sectors [11] - A collaboration with Renhe Pharmaceutical aims to create the first OTC RWA exchange, leveraging Renhe's extensive intellectual property assets for global financing [22] Financial Performance - Huajian Medical's revenue for the first half of the year was approximately RMB 12.7 billion, a decline of 6.2%, with net profit around RMB 39 million [25] - The company has historically relied on low-margin distribution of in-vitro diagnostic products, which has limited its growth potential [24] - The shift towards RWA and digital assets is seen as a necessary evolution to enhance profitability and market position [26] Market Context - The innovative drug sector faces challenges in asset tokenization due to the complexity and volatility of drug assets, which can significantly affect cash flow and investor confidence [14][16] - Huajian's strategic pivot to digital assets is part of a broader trend in the healthcare industry, where companies are exploring new financing models to address liquidity and funding challenges [29]